A233 VEDOLIZUMAB FOR STEROID & INFLIXIMAB-REFRACTORY ICI-COLITIS

BACKGROUND: Immune checkpoint inhibitors (ICI), such as anti-PD1, improve survival in melanoma, renal carcinoma and prostate cancer. However, by disinhibiting the immune system, these treatments cause significant immune-related adverse events (irAE), including colitis. For ICI-colitis, guidelines su...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Can Assoc Gastroenterol
Main Authors: Klemm, N K, Trasolini, R, Chahal, D, Donnellan, F
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Poster Presentation
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7043547/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz047.232
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki